AS03 - Let's Talk About Sex: Different aspects of Diabetes impacted by sex differences

Friday, November 28, 2025

13:00 - 14:15 Toronto

Location: Room 206

Speaker(s)

NP

Nazli Parast

Disclosure information not submitted.
ID

Irena Druce

Disclosure information not submitted.
PL

Peter Liu

Disclosure information not submitted.

Moderator(s)

James W. Kim, MBBCh, PgDip, MScCH, CPC(HC) (he/him/his)

Clinical Assistant Professor
University of Calgary
University of Calgary
Calgary, Alberta, Canada

Disclosure(s): Abbott Diabetes: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Abbvie: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Speaker/Honoraria (Ongoing); Eisai: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); EMBECTA: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); GSK: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Idorsia: Consultant (Ongoing); Lin Pharma: Advisory Board (Ongoing); Lundbeck: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); MDBriefcase: Committee/Planning Member (Terminated); Novo Nordisk Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Otsuka: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Searchlight: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Takeda Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Teva: Speaker/Honoraria (Ongoing)

Disclosure(s):

James W. Kim, MBBCh, PgDip, MScCH, CPC(HC): Abbott Diabetes: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Abbvie: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Speaker/Honoraria (Ongoing); Eisai: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); EMBECTA: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); GSK: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Idorsia: Consultant (Ongoing); Lin Pharma: Advisory Board (Ongoing); Lundbeck: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); MDBriefcase: Committee/Planning Member (Terminated); Novo Nordisk Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Otsuka: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Searchlight: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Takeda Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Teva: Speaker/Honoraria (Ongoing)

Learning Objectives:

Analyze sex-specific risk factors and clinical presentations in cardiometabolic disease to improve diagnosis and early intervention strategies;
Apply sex-informed treatment approaches across care perspectives (endocrinology, cardiology, primary care, pharmacy, nursing) to optimize patient outcomes;
Evaluate sex-based disparities in cardiometabolic care delivery and implement strategies to ensure equitable, guideline-directed therapy for all patients.